TrialArthritis & rheumatology (Hoboken, N.J.)2022

Phase II/III Results of a Trial of Anti-Tumor Necrosis Factor Multivalent NANOBODY Compound Ozoralizumab in Patients With Rheumatoid Arthritis.

Tsutomu Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.